Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110107 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 376
- Enrollment target
NCT03110107: Clinical Trial Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT03110107 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 376 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (527% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03110107, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 376 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.
Primary Outcome
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- BIOLOGICAL BMS-986218
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2024-04-04 |
| Phase | Phase 1 |
Why NCT03110107 stopped before completion
NCT03110107 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (527% higher).
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03110107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03110107 about?
NCT03110107 is a clinical study titled "First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors". The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.
What is the current status of trial NCT03110107?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 376 participants. The study started on 2017-05-04. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT03110107?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), BMS-986218 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03110107?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03110107's enrollment target sits among peer trials
376 84th of 2000 higher than 1,917 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI